Regenerative Therapy最新文献

{"title":"Canine adipose-derived mesenchymal stromal cells inhibit the growth of canine hematologic malignancy cell lines","authors":"Yuyo Yasumura ,&nbsp;Takahiro Teshima ,&nbsp;Tomokazu Nagashima ,&nbsp;Masaki Michishita ,&nbsp;Hiroki Shigechika ,&nbsp;Yoshiaki Taira ,&nbsp;Ryohei Suzuki ,&nbsp;Hirotaka Matsumoto","doi":"10.1016/j.reth.2024.12.019","DOIUrl":"10.1016/j.reth.2024.12.019","url":null,"abstract":"<div><h3>Introduction</h3><div>Intestinal lymphoma may be latent in some dogs with chronic inflammatory enteropathy. Mesenchymal stromal cells (MSCs) have potential therapeutic applications for refractory chronic inflammatory enteropathy, but their impact on the development of potential intestinal lymphomas has not yet been evaluated. Therefore, this study was performed to investigate the effect of canine adipose-derived MSCs (cADSCs) on the growth of canine lymphoma cell lines to assess the safety of MSC-based therapy in terms of pro- and anti-tumorigenic effects.</div></div><div><h3>Methods</h3><div>CADSCs were co-cultured with canine lymphoma/leukemia cell lines of various lineages, with or without cell-to-cell contact, to evaluate their effects on proliferation, apoptosis, and cell cycle progression in vitro. Additionally, a bioluminescent canine lymphoma cell line, established through firefly luciferase transduction, was co-injected with varying doses of cADSCs into immunocompromised mice. The growth of canine lymphoma cells was monitored over time in vivo using bioluminescence imaging.</div></div><div><h3>Results</h3><div>CADSCs inhibited the proliferation of all canine lymphoma/leukemia cell lines in a dose-dependent manner in vitro, under conditions allowing cell-to-cell contact. This inhibition occurred via the induction of apoptosis, G0/G1 phase cell cycle arrest, or both mechanisms. However, these effects were lost when the cells were physically separated using Transwell inserts. In xenotransplantation mouse models, cADSCs dose-dependently inhibited canine lymphoma cell growth and lung metastasis, as indicated by reduced bioluminescence signals.</div></div><div><h3>Conclusions</h3><div>This study has demonstrated for the first time that cADSCs inhibit the growth of different lineages of canine lymphoma/leukemia cells both in vitro and in vivo. These findings suggest that MSC-based cell therapy could potentially be applied to canine chronic inflammatory enteropathy without increasing the risk of promoting the growth of latent intestinal lymphomas.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 301-313"},"PeriodicalIF":3.4,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells improves cardiac function through extracellular vesicle-mediated tissue repair in a rat model of ischemic cardiomyopathy","authors":"Ryo Kawasumi ,&nbsp;Takuji Kawamura ,&nbsp;Kizuku Yamashita ,&nbsp;Yuji Tominaga ,&nbsp;Akima Harada ,&nbsp;Emiko Ito ,&nbsp;Maki Takeda ,&nbsp;Shunbun Kita ,&nbsp;Iichiro Shimomura ,&nbsp;Shigeru Miyagawa","doi":"10.1016/j.reth.2024.12.008","DOIUrl":"10.1016/j.reth.2024.12.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells (iPS-MSCs) has a therapeutic effect on myocardial ischemia. However, the therapeutic mechanism underlying systemic iPS-MSC-based therapy for ischemic cardiomyopathy (ICM) remains unclear. We investigated the therapeutic effects of iPS-MSCs through extracellular vesicle (EV)-mediated tissue repair in a rat model of ICM.</div></div><div><h3>Methods</h3><div>A rat ICM model was created by left anterior descending coronary artery ligation. iPS-MSCs were administered intravenously every week for four weeks in the iPS-MSC group, whereas saline was administered to the control group. Alix, a protein involved in the biogenesis of EVs, was knocked down, and Alix-knockdown iPS-MSCs were administered to the siAlix group. We analyzed sequential cardiac function using echocardiography, histological analysis, cell tracking analysis with fluorescent dyes, and comprehensive RNA sequencing of the border zone of the myocardium after treatment.</div></div><div><h3>Results</h3><div>Left ventricular ejection fraction (LVEF) was significantly improved in the iPS-MSC group compared with that in the control group. In the siAlix group, LVEF was significantly lower than that in the iPS-MSC group. Histological analysis showed a significant decrease in fibrosis area and significant increase in microvascular density in the iPS-MSC group. A cell-tracking assay revealed iPS-MSC accumulation in the border zone of the myocardium during the acute phase. Comprehensive microRNA sequencing analysis revealed that EVs from iPS-MSCs contained miRNAs associated with anti-fibrosis and angiogenesis. Gene ontology analysis of differentially expressed genes in myocardial tissue also showed upregulation of pathways related to antifibrosis and neovascularization and downregulation of pathways linked to inflammation and T-cell differentiation.</div></div><div><h3>Conclusions</h3><div>Systemic administration of iPS-MSCs improved cardiac function through EV-mediated angiogenetic and antifibrotic effects in an ICM, suggesting the clinical possibility of treating chronic heart failure.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 253-261"},"PeriodicalIF":3.4,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral-based gene therapy clinical trials for immune deficiencies and blood disorders from 2013 until 2023 - an overview","authors":"Shirin Eshghi ,&nbsp;Mahsa Mousakhan Bakhtiari ,&nbsp;Maryam Behfar ,&nbsp;Elaheh Izadi ,&nbsp;Parisa Naji ,&nbsp;Leila Jafari ,&nbsp;Rashin Mohseni ,&nbsp;Zohreh Saltanatpour ,&nbsp;Amir Ali Hamidieh","doi":"10.1016/j.reth.2024.12.007","DOIUrl":"10.1016/j.reth.2024.12.007","url":null,"abstract":"<div><div>Gene therapy (GT) as a groundbreaking approach holds promise for treating many diseases including immune deficiencies and blood disorders. GT can benefit patients suffering from these diseases, especially those without matched donors or who are at risk after hematopoietic stem cell transplantation (HSCT). Due to all the advances in the field of GT, its main challenge is still gene delivery. Generally, gene delivery systems are categorized into two types depending on utilized vectors: non-viral and viral. Viral vectors are commonly used in GT because of their high efficiency compared to non-viral vectors. In this article, all clinical trials on viral-based GT (with the exclusion of CRISPR and CAR-T cell Therapy) in the last decade for immune deficiencies and blood disorders including Severe combined immune deficiency (SCID), Wiskott-Aldrich syndrome (WAS), Chronic granulomatous disease (CGD), Leukocyte adhesion deficiency (LAD), Fanconi anemia (FA), Hemoglobinopathies, and Hemophilia will thoroughly be discussed. Moreover, viral vectors used in these trials including Retroviruses (RVs), Lentiviruses (LVs), and Adeno-Associated Viruses (AAVs) will be reviewed. This review provides a concise overview of traditional treatments for the mentioned disease and precise details of their viral-based GT clinical trial studies in the last decade, then presents the advantages, disadvantages, and potential adverse events of GT. In conclusion, this review presents GT as a hopeful and growing field in healthcare that could offer cures to diseases that were previously thought to be untreatable.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 262-279"},"PeriodicalIF":3.4,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interplay between pioneer transcription factors and epigenetic modifiers in cell reprogramming","authors":"Gerardo Mirizio ,&nbsp;Samuel Sampson ,&nbsp;Makiko Iwafuchi","doi":"10.1016/j.reth.2024.12.014","DOIUrl":"10.1016/j.reth.2024.12.014","url":null,"abstract":"<div><div>The generation of induced pluripotent stem cells (iPSCs) from differentiated somatic cells by Yamanaka factors, including pioneer transcription factors (TFs), has greatly reshaped our traditional understanding of cell plasticity and demonstrated the remarkable potential of pioneer TFs. In addition to iPSC reprogramming, pioneer TFs are pivotal in direct reprogramming or transdifferentiation where somatic cells are converted into different cell types without passing through a pluripotent state. Pioneer TFs initiate a reprogramming process through chromatin opening, thereby establishing competence for new gene regulatory programs. The action of pioneer TFs is both influenced by and exerts influence on epigenetic regulation. Despite significant advances, many direct reprogramming processes remain inefficient, which limits their reliability for clinical applications. In this review, we discuss the molecular mechanisms underlying pioneer TF-driven reprogramming, with a focus on their interactions with epigenetic modifiers, including Polycomb repressive complexes (PRCs), nucleosome remodeling and deacetylase (NuRD) complexes, and the DNA methylation machinery. A deeper understanding of the dynamic interplay between pioneer TFs and epigenetic modifiers will be essential for advancing reprogramming technologies and unlocking their full clinical potential.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 246-252"},"PeriodicalIF":3.4,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel preparation of laponite based theranostic silver nanocomposite for drug delivery, radical scavenging and healing efficiency for wound care management after surgery","authors":"Lizhen Long ,&nbsp;Xiaoan Ma ,&nbsp;Hua Zhang ,&nbsp;Changgong Lan","doi":"10.1016/j.reth.2024.12.004","DOIUrl":"10.1016/j.reth.2024.12.004","url":null,"abstract":"<div><div>In this work, laponite (LAP) was used to develop the silver (Ag) based nanocomposite for improved anti-bacterial action and wound healing properties. The amphiphilic co-polymers such as PLGA polymer was embedded with the surface of LAP molecules and polyethyleneimine (PEI) through the interaction of hydrophobic binding and it was formed as LAP/PLA-PEG/PEI formulation through the coupling chemistry. The Ag nanoparticles was loaded into formulation to develop LAP/PLA-PEG/PEI/Ag nanocomposite and characterized by different analytical techniques. The UV–Vis and XRD results report that the nanocomposite has shown Surface Plasmon Resonance (SPR) peak at 415 nm for AgNPs particles and provide the strong intensity peak along with 48 nm particle size, respectively. The HR-TEM image showed that the LAP/PLA-PEG/PEI/Ag nanocomposite has shown crystal lattice with spherical morphology. In addition, the synthesized nanocomposite requested in the swelling along with degradation, radial scavenging activity and drug releasing behaviour by <em>in vitro</em> method. The anti-bacterial analysis results showed that the nanocomposite have greater bacterial inhibition. Moreover, <em>In vitro</em> cell model and <em>In vivo</em> wound healing studies confirmed that nanocomposite have significant biocompatibility and healing properties. Importantly, <em>in vivo</em> histological analyses confirmed the effective wound healing effect of nanocomposite by complete re-epithelialization, formation of new granulation tissue and blood vessels. These observations provide strong evidences to use this novel nanoformulation for wound healing application with anti-microbial action.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 235-245"},"PeriodicalIF":3.4,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline magnetic resonance imaging findings associated with short-term clinical outcomes after intraarticular administration of autologous adipose-derived stem cells for knee osteoarthritis","authors":"Ryota Yamagami ,&nbsp;Tomohiro Terao ,&nbsp;Taro Kasai ,&nbsp;Hisatoshi Ishikura ,&nbsp;Masaki Hatano ,&nbsp;Junya Higuchi ,&nbsp;Shuichi Yoshida ,&nbsp;Yusuke Arino ,&nbsp;Ryo Murakami ,&nbsp;Masashi Sato ,&nbsp;Yuji Maenohara ,&nbsp;Yuma Makii ,&nbsp;Tokio Matsuzaki ,&nbsp;Keita Inoue ,&nbsp;Shinsaku Tsuji ,&nbsp;Sakae Tanaka ,&nbsp;Taku Saito","doi":"10.1016/j.reth.2024.12.012","DOIUrl":"10.1016/j.reth.2024.12.012","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to determine the association between the baseline magnetic resonance imaging (MRI) findings and clinical outcomes after articular injection of adipose-derived mesenchymal stem cells (ASCs) for knee osteoarthritis (KOA).</div></div><div><h3>Methods</h3><div>This retrospective study included 149 patients with varus-type KOA treated with a single intraarticular ASC injection. All patients underwent a MRI evaluation before treatment. Patients were categorized following the MRI Osteoarthritis Knee Score (MOAKS) system cartilage score into the mild, moderate, or severe KOA groups. Additionally, joint effusion and synovitis, bone marrow lesions (BMLs), and meniscal extrusions were graded with the MOAKS. Knee Osteoarthritis Outcome Score (KOOS) was obtained at baseline, 1-, 3-, 6-, and 12-month posttreatment. The responder rate in the Outcome Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International was assessed with the KOOS. Multivariate logistic regression analyses were conducted to determine factors associated with the responder rate.</div></div><div><h3>Results</h3><div>All KOOS subscales significantly enhanced with the greatest improvement from baseline to 6 months which plateaued between 6 and 12 months. The responder rate was 65.4 % in the mild/moderate KOA compared to 35.2 % in the severe KOA at 12 months. Lower OA grade (odds ratio [OR]: 0.52; 95 % confidence interval (CI): 0.31–0.88; <em>P</em> = 0.015), smaller BMLs in medial femoral condyle (OR: 0.36; 95 % CI: 0.14–0.94; <em>P</em> = 0.037), and less meniscal extrusion (OR: 0.31; 95 % CI: 0.11–0.89; <em>P</em> = 0.029) were associated with higher responder rate at 6 months in multivariable logistic regression analysis. The factors associated with higher responder rate at 12 months included lower OA grade (OR: 0.42; 95 % CI: 0.25–0.73; <em>P</em> = 0.002) and younger age (OR: 1.04; 95 % CI: 1.00–1.08; <em>P</em> = 0.042).</div></div><div><h3>Conclusions</h3><div>ASC treatment for KOA enhanced short-term clinical outcomes. MRI findings, including cartilage lesions, BMLs, and meniscal extrusion, were associated with responder rate, helping physicians identify which patients may benefit from this therapy.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 227-234"},"PeriodicalIF":3.4,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of GATA4 in mesenchymal stem cell senescence: A new frontier in regenerative medicine","authors":"M. Arockia Babu ,&nbsp;Renuka Jyothi S ,&nbsp;Irwanjot Kaur ,&nbsp;Sachin Kumar ,&nbsp;Naveen Sharma ,&nbsp;M. Ravi Kumar ,&nbsp;Pranchal Rajput ,&nbsp;Haider Ali ,&nbsp;Gaurav Gupta ,&nbsp;Vetriselvan Subramaniyan ,&nbsp;Ling Shing Wong ,&nbsp;Vinoth Kumarasamy","doi":"10.1016/j.reth.2024.11.017","DOIUrl":"10.1016/j.reth.2024.11.017","url":null,"abstract":"<div><div>The Mesenchymal Stem Cell (MSC) is a multipotent progenitor cell with known differentiation potential towards various cell lineage, making it an appealing candidate for regenerative medicine. One major contributing factor to age-related MSC dysfunction is cellular senescence, which is the hallmark of relatively irreversible growth arrest and changes in functional properties. GATA4, a zinc-finger transcription factor, emerges as a critical regulator in MSC biology. Originally identified as a key regulator of heart development and specification, GATA4 has since been connected to several aspects of cellular processes, including stem cell proliferation and differentiation. Accumulating evidence suggests that the involvement of GATA4-nuclear signalizing in the process of MSC senescence-related traits may contribute to age-induced alterations in MSC behavior. GATA4 emerged as the central player in MSC senescence, interacting with several signaling pathways. Studies have shown that GATA4 expression is reduced with age in MSCs, which is associated with increased expression levels of senescence markers and impaired regenerative potential. At the mechanistic level, GATA4 regulates the expression of genes involved in cell cycle regulation, DNA repair, and oxidative stress response, thereby influencing the senescence phenotype in MSCs. The findings underscore the critical function of GATA4 in MSC homeostasis and suggest a promising new target to restore stem cell function during aging and disease. A better understanding of the molecular mechanisms that underlie GATA4 mediated modulation of MSC senescence would provide an opportunity to develop new therapies to revitalize old MSCs to increase their regenerative function for therapeutic purposes in regenerative medicine.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 214-226"},"PeriodicalIF":3.4,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MAPT-A152T mutation drives neuronal hyperactivity through Fyn-NMDAR signaling in human iPSC-Derived neurons: Insights into Alzheimer's pathogenesis","authors":"Maika Itsuno ,&nbsp;Hirokazu Tanabe ,&nbsp;Etsuko Sano ,&nbsp;Takashi Sasaki ,&nbsp;Chisato Oyama ,&nbsp;Hiroko Bannai ,&nbsp;Koichi Saito ,&nbsp;Kazuhiko Nakata ,&nbsp;Setsu Endoh-Yamagami ,&nbsp;Hideyuki Okano ,&nbsp;Sumihiro Maeda","doi":"10.1016/j.reth.2024.12.009","DOIUrl":"10.1016/j.reth.2024.12.009","url":null,"abstract":"<div><h3>Introduction</h3><div>Tau protein plays a pivotal role in the pathogenesis of Alzheimer's disease (AD) and in regulating neuronal excitability. Among tau-coding microtubule associated protein tau (<em>MAPT</em>) gene mutations, the A152T mutation is reported to increase the risk of AD and neuronal excitability in mouse models.</div></div><div><h3>Methods</h3><div>To investigate the effects of <em>MAPT</em> gene expression and its mutations on neuronal activity in human neurons, we employed genome editing technology to introduce the A152T or P301S mutations into induced pluripotent stem cells (iPSCs). We then differentiated them into excitatory and inhibitory neurons. As a control, iPSCs in which the <em>MAPT</em> gene was replaced with a fluorescent protein were also created.</div></div><div><h3>Results</h3><div>In excitatory neuronal cultures, the A152T mutation was found to enhance spontaneous neuronal activity and the association of tau and Fyn. However, in inhibitory neuron-enriched cultures, the A152T mutation did not affect neuronal activity. Inhibition of NMDA receptors (NMDAR) and the reduction of tau protein levels decreased neuronal excitability in both A152T/A152T and healthy control (WT/WT) excitatory neurons. In addition, the A152T mutation increased the interaction between tau and Fyn. These findings suggest that the tau-Fyn interaction plays a critical role in regulating neuronal activity under physiological conditions, while the A152T mutation enhances neuronal activity by strengthening this endogenous interaction between tau and Fyn. In addition, transcriptomic analysis revealed structural changes specific to excitatory neurons with the A152T mutation. Common changes observed in both A152T and P301S lines recapitulated a dedifferentiation phenotype, consistent with previous reports.</div></div><div><h3>Conclusions</h3><div>These data demonstrate that the A152T mutation in the <em>MAPT</em> gene increases neuronal excitability through the tau-Fyn-NMDAR pathway in excitatory neurons, shedding light on its role in AD pathogenesis.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 201-213"},"PeriodicalIF":3.4,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cell therapy for bladder regeneration: A comprehensive systematic review","authors":"Ali Faegh ,&nbsp;Shima Jahani ,&nbsp;Fatemeh Chinisaz ,&nbsp;Hamoon Baghaei ,&nbsp;Masoumeh Majidi Zolbin","doi":"10.1016/j.reth.2024.12.005","DOIUrl":"10.1016/j.reth.2024.12.005","url":null,"abstract":"<div><div>Tissue engineering has been considered a potential choice for urinary system reconstruction. Here, we aim to a broad spectrum of employed stem cells in bladder regeneration by performing a comprehensive systematic review. In January 2024, we searched Scopus, PubMed, and Embase databases for studies that tried bladder regeneration by tissue engineering using stem cells. We excluded non-English studies, review articles, and manuscripts that met the other exclusion criteria. Among 43 included studies, comparative studies demonstrated the similar or superior potentiality of stem cells to regenerate tissues and improve bladder function compared with autologous cells. Furthermore, data suggest an increased use of bio-synthetic scaffolds and their appropriate bio-compatibility with stem cells. The evidence establishes that adipose-derived and bone marrow-derived mesenchymal stem cells are the most frequently used stem cells. And both are suitable for urothelium and smooth muscle formation along with the capability of bone marrow-derived mesenchymal stem cells for lamina propria formation. Additionally, the competency of smooth muscle-derived progenitor cells, urine-derived stem cells, umbilical mesenchymal SCs for smooth muscle and urothelium regeneration, and the capability of hair follicle stem cells for smooth muscle formation are demonstrated. Also, the superiority of endothelial progenitor cells for neo-vascularization and smooth muscle progenitor cells for neuron formation are demonstrated. In addition to adding growth factors to the culturing media, hypoxic conditions and intra-peritoneal incubation are introduced as promoter conditions that can improve histological and physiological components. Available evidence is limited, although it suggests the precious capability of stem cells for bladder regeneration.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 191-200"},"PeriodicalIF":3.4,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardizing decellularization protocols for optimized uterine tissue bioengineering","authors":"Edina Sehic ,&nbsp;Lucía de Miguel-Gómez","doi":"10.1016/j.reth.2024.12.011","DOIUrl":"10.1016/j.reth.2024.12.011","url":null,"abstract":"<div><div>Bioengineering is applied in different areas, including women's infertility management. Among other approaches, decellularized tissues are being used to treat uterine disorders causing infertility. Biomaterials made from decellularized tissue consist of tissue-specific extracellular matrix and, as acellular scaffolds, are thought to be immune inert. Hence, they are good grafting candidates to replace and regenerate excised damaged uterine tissue to cure infertility. However, decellularization approaches differ among species and research groups, posing challenges for comparison and standardization. The diversity in data reporting and studied properties of the resulting decellularized scaffold make it even more difficult, especially when the ultimate goal is clinical translation. Thus, this review aims to critically assess whole uterus decellularization studies, extracting and comparing their main results and conclusions. After carefully evaluating the reviewed studies, we noticed that the vast majority base the uterus decellularization success and resulting scaffold efficacy on the DNA removal efficacy, while other crucial aspects, including the extracellular matrix integrity or immunogenicity, are underestimated. Thus, this review further proposes practical points for what should be considered and how results can be reported in studies involving whole uterus decellularization to facilitate comparison between studies and translational progress.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"28 ","pages":"Pages 183-190"},"PeriodicalIF":3.4,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}